Available Technologies
# of Displayed Technologies: 5 / 5
Applied Category Filter (Click To Remove): Oncology
Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
The Need
Despite the crucial role of androgen receptors (AR) in HCC progress…
- College: College of Pharmacy
- Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
- Licensing Officer: Schultz, Teri
Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Pharmacy
- Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
- Licensing Officer: Taysavang, Panya
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 —
Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
- College: College of Medicine (COM)
- Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
- Licensing Officer: He, Panqing
Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
- Licensing Officer: Taysavang, Panya
